4//SEC Filing
Blackwell Kimberly 4
Accession 0001725160-22-000005
CIK 0001725160other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:49 PM ET
Size
8.6 KB
Accession
0001725160-22-000005
Insider Transaction Report
Form 4
Blackwell Kimberly
Director
Transactions
- Exercise/Conversion
Common Stock
2022-01-03$47.80/sh+1,000$47,800→ 6,000 total - Sale
Common Stock
2022-01-03$83.74/sh−1,000$83,740→ 5,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-01-03−1,000→ 38,000 totalExercise: $47.80Exp: 2030-06-30→ Common Stock (1,000 underlying)
Footnotes (2)
- [F1]The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2021.
- [F2]The options vest and become exercisable in substantially equal monthly installments over the 36 months following the date of grant on July 1, 2020.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001816465
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 5:49 PM ET
- Size
- 8.6 KB